Benevira, Inc.
Benevira is a global, privately owned synthetic biology company focused on developing sustainable antiviral treatments to protect against viral infections. The company aims to address the challenges of evolving viruses by targeting viral evolutionary bottlenecks, and is dedicated to supplying antivirals globally. Benevira's mission is to develop therapeutics and prophylactics for various viral indications, including SARS-CoV-2, HPV, RSV, MERS, Variola, and Influenza, with the potential for broad-spectrum antivirals.
Industries
Nr. of Employees
small (1-50)
Benevira, Inc.
201 East 36th Street #5F, New York, NY, 10016
Products
Lead SARS‑CoV‑2 antiviral candidate (preclinical)
A preclinical antiviral candidate developed to target functional viral components unlikely to evolve; reported in vitro efficacy against multiple SARS‑CoV‑2 variants and favorable tolerability in an animal model.
Lead SARS‑CoV‑2 antiviral candidate (preclinical)
A preclinical antiviral candidate developed to target functional viral components unlikely to evolve; reported in vitro efficacy against multiple SARS‑CoV‑2 variants and favorable tolerability in an animal model.
Services
Discovery services using synthetic biology and computational design to identify antiviral candidates that target conserved viral elements.
In vitro and in vivo preclinical testing services to evaluate antiviral efficacy and tolerability prior to clinical development.
Formulation and product development for finished-dose antiviral products intended for self-administration.
Development and manufacture of biologics, therapeutics, and consumer health products from internal pipeline efforts.
Discovery services using synthetic biology and computational design to identify antiviral candidates that target conserved viral elements.
In vitro and in vivo preclinical testing services to evaluate antiviral efficacy and tolerability prior to clinical development.
Formulation and product development for finished-dose antiviral products intended for self-administration.
Development and manufacture of biologics, therapeutics, and consumer health products from internal pipeline efforts.
Expertise Areas
- Synthetic biology
- Antiviral drug discovery
- Preclinical development and testing
- AI-driven computational design
Key Technologies
- Synthetic biology methods
- AI-driven computational design
- Cell-based antiviral assays
- Animal model preclinical testing
News & Updates
Benevira was awarded a presentation position at BioNJ, a biopartnering conference in Jersey City, NJ, where Dr. Roee Amit, CTO, presented.
Benevira was selected to present at the 23rd annual New York Venture Summit, connecting with investors and industry leaders to secure funding.
Benevira announced positive preclinical safety and efficacy data on β521, a novel SARS-CoV-2 therapy, demonstrating 99% effectiveness against variants and 100% tolerability in animal studies.
Benevira was awarded a presentation position at BioNJ, a biopartnering conference in Jersey City, NJ, where Dr. Roee Amit, CTO, presented.
Benevira was selected to present at the 23rd annual New York Venture Summit, connecting with investors and industry leaders to secure funding.
Benevira announced positive preclinical safety and efficacy data on β521, a novel SARS-CoV-2 therapy, demonstrating 99% effectiveness against variants and 100% tolerability in animal studies.